Currently, Continuous intraperitoneal insulin infusion (CIPII) is used as a last‐resort treatment option for selected patients with type 1 diabetes mellitus (T1DM) who fail to reach glycaemic control despite intensive subcutaneous (SC) insulin therapy. This evidence concerns the gene INS and diabetes mellitus.